- HIV market to be worth $16B by 2019.
- Calimmune, Johnson & Johnson and many universities pioneering pre-clinical and clinical studies using ddRNAi to treat HIV.
- Benitec Biopharma has seminal ddRNAi patents.
- One clinical trial completed and two more currently active.
- A one-off treatment could provide a lifetime of protection against HIV/AIDS.
There are no Transcripts on BTEBY.
We currently have no Breaking News on this stock.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
BTEBY vs. ETF Alternatives
Currently, there's no company description for BTEBY.
Other News & PR